About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Light Therapy on Major Depression Disorder

Clinicaltrials.gov identifier NCT03941301

Recruitment Status Recruiting

First Posted May 7, 2019

Last update posted July 9, 2019

Study Description

Brief summary:

Background: Major depression disorder is a common psychological disease. It is the second-ranked cause of disability worldwide. The pathophysiology is not yet understood. The main theory is monoaminergic theory based on the effect of monoaminergic drugs. Current treatment includes psychotherapy, medication and electroconvulsive therapy. The onset of action for antidepressant is often slow, therefore strategies to improve the outcome are important. Bright light therapy has been found to be effective in reducing the severity of depression not only in seasonal affective disorder but also in other affective disorder. Previous meta-analyses of light therapy for non-seasonal major depression, however, has yielded conflicting evidence for efficacy. Purpose: 1. To investigate possible imaging biomarkers of major depression disorder 2. To evaluate the effect of light therapy on depression Materials and Methods: This prospective study will recruit 100 patients, randomized into 2 study groups: (1) antidepressant plus treatment light, and (2) antidepressant plus placebo light. All patients will accept a thorough psychological evaluation (including Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, Clinical Global Impression-Severity and Patient Health Questionnaire-9 items) at baseline and at the 1st, 2nd, 4th, 8th week during the 8-week experiment intervention, by a blind assessor. Mini-International Neuropsychiatric Interview (MINI) and Morningness- Eveningness Questionnaire-Self-Assessment Version (MEQ-SA) were only evaluated at baseline. Adverse events were evaluated at baseline, 2nd,4th,8th weeks. MRI study will be arranged at baseline and in 4-week experiment. Predicted Results and Influence: 1. To evaluate the additional effect of the treatment light on depression disorder 2. To compare the difference of functional magnetic resonance imaging(fMRI), structural MRI among the two groups and between the patients with and without treatment effect in order to detect imaging biomarkers.

  • Condition or Disease:Depressive Disorder
  • Intervention/Treatment: Device: Light therapy
  • Phase: N/A
Detailed Description


Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 100 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Care Provider, Investigator)
  • Primary Purpose: Treatment
  • Official Title: Light Therapy on Major Depression Disorder
  • Actual Study Start Date: May 2019
  • Estimated Primary Completion Date: December 2019
  • Estimated Study Completion Date: December 2019
Arms and interventions
Arm Intervention/treatment
Active Comparator: Bright treatment light
Device: Light therapy
Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
Placebo Comparator: Red light
Device: Light therapy
Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
Outcome Measures
  • Primary Outcome Measures: 1. Change from Baseline Hamilton Depression Rating Scale(HAM-D) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]
    Determine severity of depression (scores: 0-50) Depressed Mood (sadness, hopeless, helpless, worthless) (0-4 scores) Feelings of Guilt(0-4 scores) Suicide(0-4 scores) Insomnia - Early(0-2 scores) Insomnia - Middle(0-2 scores) Insomnia - Late(0-2 scores) Work and Activities(0-4 scores) Retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity)(0-4 scores) Agitation(0-2 scores) Anxiety - Psychic(0-4 scores) Anxiety - Somatic(0-4 scores) Somatic Symptoms - Gastrointestinal(0-2 scores) Somatic Symptoms - General(0-2 scores) Genital Symptoms(0-2 scores) Hypochondriasis(0-4 scores) Loss of Weight(0-2 scores) Insight(0-2 scores) Scores below 7 generally represent the absence or remission of depression. Scores between 7-17 represent mild depression. Scores between 18-24 represent moderate depression. Scores 25 and above represent severe depression.
  • 2. Change from Baseline Montgomery-Asberg Depression Rating Scale(MADRS) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]
    Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
  • 3. Change from Baseline Clinical Global Impression-Severity(CGI-S) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]
    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: Normal, not at all ill Borderline mentally ill Mildly ill Moderately ill Markedly ill Severely ill Among the most extremely ill patients
  • 4. Change from Baseline Patient Health Questionnaire(PHQ-9) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]
    Depression screening by a nine-item in adults Over the last two weeks, how often have you been bothered by any of the following problems? (Scores: 0-27) 0:Not at all, 1:Several days, 2:More than half the days, 3:Nearly every day Little interest or pleasure in doing things Feeling down, depressed, or hopeless Trouble falling or staying asleep, or sleeping too much Feeling tired or having little energy Poor appetite or overeating Feeling bad about yourself, or that you are a failure, or have let yourself or your family down Trouble concentrating on things, such as reading the newspaper or watching television Moving or speaking so slowly that other people could have noticed? Or the opposite, being so fidgety or restless that you have been moving around a lot more than usual Thoughts that you would be better off dead or of hurting yourself in some way 0-4:No depression, 5-9:Mild, 10-14:Moderate, 15-19:Moderately severe, 20-27: Severe
  • Secondary Outcome Measures: 1. functional MRI [ Time Frame: 4 weeks ]
    Compare brain resting-state functional MRI change between these two arms. Including measures brain activity by detecting changes associated with blood flow and difference of Resting State Network which is a functionally connected neural network of apparent brain states. Increased strength of the activities or resting state network indicates neural activities are elevated within the regions of the brain or the network. Decreased strength of the activities or resting state network indicates neural activities are diminished within the regions of the brain or the network.
  • 2. Diffusion Tensor Imaging of MRI [ Time Frame: 4 weeks ]
    Compare brain Diffusion Tensor Imaging between these two arms. Evaluation the connection or fiber tracts between regions of the brain. Increased strength means enhanced connection between neuronal regions of the brain. Decreased strength means decreased connection between neuronal regions of the brain.
Eligibility Criteria
  • Ages Eligible for Study: 20 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Fulfill diagnosis of Major depression disorder based on Diagnostic and Statistical
Manual of Mental Disorders(DSM-V) for at least 6 weeks and under medication treatment
for at least 4 weeks.

2. at least 20 years old

3. Hamilton Depression Rating Scale(HAMD-17) >= 13

4. No medication change for at least 4 weeks and no medication change will be considered
in the next 8 weeks.

5. Agree to participate in this study and sign the permit.

Exclusion Criteria:

1. Seasonal depression disorder

2. Other psychological or neurological disorder

3. Drug or alcohol abuse within 30 days

4. Visual problem

5. Light-induced seizure or migraine

6. Contraindication for MRI study

7. Severe illness and might be admitted in the near future

8. Might have a long trip in the near future

Contacts and Locations

Contact: Chun-Chao Huang 886-975835637 hcc.5306@mmh.org.tw


Mackay Memorial Hospital

Sponsors and Collaborators

Mackay Memorial Hospital

National Tsing Hua University,Taiwan

Ministry of Science and Technology, Taiwan


Principal Investigator: Chun-Chao Huang Mackay Memorial Hospital

More Information
  • Responsible Party: Mackay Memorial Hospital
  • ClinicalTrials.gov Identifier: NCT03941301 History of Changes
  • Other Study ID Numbers: 18MMHIS114e
  • First Posted: May 7, 2019 Key Record Dates
  • Last Update Posted: July 9, 2019
  • Last Verified: July 2019
  • Individual Participant
    Data (IPD) Sharing
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Depressive Disorder Depression